Adalimumab Market Analysis: by Applications (Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, and Others) and Geography - Forecast 2016-2021

Description:
Adalimumab, which is a patent product of the Abott Biotechnology Ltd., is a medication used for treatment of ulcerative colitis, psoriatic arthritis and rheumatoid arthritis. It also known as HUMIRA, intended to inject subcutaneously. Side effects of this product are vomiting, nausea, internal bleeding, psoriasis, anaphylaxis, respiratory tract infections, hepatitis B infection, liver injuries and headache etc. Invented by Jochen Salfeld, Adalimumab is accessible as a pre-filled, single use syringe. In December 2002, the U.S. FDA approved adalimumab for indications such as psoriatic arthritis, Crohn's disease, plaque psoriasis, ankylosing spondylitis, rheumatoid arthritis and ulcerative colitis etc.

Rising occurrence of arthritis is among the key drivers boosting the growth of the this market. The population of women is at a greater chance of arthritis because of huge loss of calcium from the body in comparison to the males. This is expected to fuel demand for adalimumab over the forecast period. Furthermore, the sedentary lifestyle of people across the globe aids in increasing arthritis prevalence. As per the Centre of Disease Prevention and Control, a large number of adults in U.S. have been found to have rheumatoid arthritis, arthritis, lupus, fibromyalgia and gout. However, increasing prices of adalimumab is among the key hindrance to the global market.

Adalimumab market is classified into applications as Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis and Others. Further, the Global Adalimumab Market is bifurcated by regions into North America, Asia Pacific (APAC), Europe and Rest of the World. Presently, Europe and North America account for the largest market share in the global market. Factors that include advanced healthcare infrastructure and reimbursement coverage and availability of well-organized regulatory framework are the major drivers of the adalimumab market in Europe and North America market. Followed by which, Asia Pacific market is expected to witness a significant rise during the forecast period due to factors like rising disposable income, rapidly developing healthcare infrastructure and municipality/government measures to improve the healthcare sector. India and China amount as the highest population globally. Therefore, geriatric population across India and China is analyzed to grow in the near future as a result of which the adalimumab market is expected to witness a growth in the market. Abundance of geriatric population is further analyzed to bolster the anti-arthritis drugs demand.

Some of the key players in the global Adalimumab market include:
AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), Pfizer, Inc. (U.S.), Novartis AG(Switzerland) and Mylan N.V.(U.S.) among others.

Contents:
1. Adalimumab- Market Overview
2. Executive Summary
3. Adalimumab- Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Patent Analysis
      3.2.4. Top 5 Financials Analysis
4. Adalimumab- Market Forces
   4.1. Market Drivers
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Adalimumab Industry
      4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Adalimumab Market - Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Suppliers/Distributors Analysis
6. Adalimumab Market - By Applications:
   6.1. Introduction
   6.2. Rheumatoid Arthritis,
   6.3. Psoriasis,
   6.4. Chron's Disease,
   6.5. Ulcerative Colitis and
   6.6. Others
7. Adalimumab Market - By Geography:
   7.1. Introduction
   7.2. North America
      7.2.1. U.S.
      7.2.2. Canada
      7.2.3. Mexico
      7.2.4. Rest of North America
   7.3. Europe
      7.3.1. France
      7.3.2. Germany
      7.3.3. Italy
      7.3.4. Spain
      7.3.5. U.K
      7.3.6. Rest of Europe
   7.4. APAC
      7.4.1. Australia
      7.4.2. China
      7.4.3. India
      7.4.4. Japan
      7.4.5. Rest of APAC
   7.5. ROW
      7.5.1. Middle East & Africa
      7.5.2. South America
8. Market Entropy
8.1. New Product Launches
8.2. M&As, Collaborations, JVs and Partnerships
9. Company Profiles
   9.1. AbbVie, Inc.,
   9.2. Amgen, Inc.,
   9.3. Pfizer, Inc.,
   9.4. Novartis AG,
   9.5. Mylan N.V.,
   9.6. Boehringer Ingelheim GmbH and
   9.7. Merck & Co.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
**Financials would be provided on a best efforts basis for private companies**
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Adalimumab Market Analysis: by Applications (Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, and Others) and Geography - Forecast 2016-2021
Web Address: http://www.researchandmarkets.com/reports/3820901/
Office Code: SCH375JJ

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 - 5 Users:</td>
<td></td>
<td>USD 5250</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
<td>USD 6250</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
<td>USD 8450</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: _Mr_ [ ] _Mrs_ [ ] _Dr_ [ ] _Miss_ [ ] _Ms_ [ ] _Prof_ [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * _______________________
Job Title: ____________________________
Organisation: _________________________
Address: ______________________________
City: _________________________________
Postal / Zip Code: _____________________
Country: ______________________________
Phone Number: _________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World